RecruitingNCT04946721

2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study


Sponsor

University of Maryland, Baltimore

Enrollment

150 participants

Start Date

Apr 27, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Evaluate and study the immunologic changes to the ocular surface in cancer patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying The standard care exam and biological specimens' collection for people with dry-eye disease and ogvhd. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTThe standard care exam and biological specimens' collection

During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.


Locations(1)

Geenebaum Cancer Center, University of Maryland Medical Center

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04946721


Related Trials